Evolution of the Resistance to Several Antibiotics in Helicobacter pylori over a Four-Year Period

  • Manuel López-Brea
  • Maria Jose Martinez
  • Diego Domingo
  • Isabel Sanchez Romero
  • Juan Carlos Sanz
  • Teresa Alarcón

Abstract

A variety of antimicrobial agents display good activity against H. pylori in vitro, but when using as single agent in clinical studies, they do not succeed in eradicating the organism. Several regimes have been proposed in the treatment of the pathology produced by H. pylori with at least 2 or 3 drugs, including one or two antibiotics and other compounds such as bismuth salts and proton pump inhibitors as omeprazole, lansoprazole and pantoprazole, that have shown activity against the microorganism with minimal inhibitory concentrations (MICs) of 16–64 mg/l9. Amoxicillin, tetracycline, metronidazole and clarithromycin are the most frequent antimicrobial agents used for the treatment of H. pylori infection.

Keywords

Minimal Inhibitory Concentration Proton Pump Inhibitor Resistance Rate Pylorus Strain Blood Agar Plate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alarcón T., Garcia Arata I., Martinez M.J., Villar H., Sanz J.C., López-Brea M. (1994) Am. J. Gastroenterol. 89, 1363.Google Scholar
  2. 2.
    Cederbrant G., Kahlmeter G., Ljungh A. (1991) J. Antimicrob. Chemother., 29, 115–120.CrossRefGoogle Scholar
  3. 3.
    Glupczynski Y, Delmee C., Labbe M., Avesani V., Burette A. (1988) Eur J Epidemiol., 4, 154–157.PubMedCrossRefGoogle Scholar
  4. 4.
    Glupczynski Y., Goutier S., Van den Borre C., Butzler J.P., Burette A. (1995). Gut, 37(suppl 1), A 56.Google Scholar
  5. 5.
    Goodwin C.S., Blake P., Blincow E. (1986) J. Antimicrob Chemother., 17, 309–314.PubMedCrossRefGoogle Scholar
  6. 6.
    Hoffman P.S., Goodwin A., Johnsen J., Veldhuyzen van Zanten S. (1995). Gut, 37(suppl 1), A 66.Google Scholar
  7. 7.
    Lacey S.L., Moss S.F., Taylor G.W. (1993) J. Antimicrob. Chemother., 32, 393–400.PubMedCrossRefGoogle Scholar
  8. 8.
    López-Brea M., Martín E., López Lavid C., Sanz J.C. (1991) Eur. J. Clin. Microbiol. Infect. Dis. 10, 1082–1083.PubMedCrossRefGoogle Scholar
  9. 9.
    Megraud F., Boyanova L., Lamouliatte H. (1991) Lancet, 1, 1486.CrossRefGoogle Scholar
  10. 10.
    Nair P., McNulty C.A.M. (1995). Gut, 37(suppl 1), A 46.Google Scholar
  11. 11.
    Versalovic J., Kibler K., Small S., Graham D.Y, Go M.F. (1995). Gut, 37(suppl 1), A 67.Google Scholar
  12. 12.
    Yang J.C., Yang C.K, Wang J.T, Wang T.H. (1995). Gut, 37(suppl 1), A 70.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Manuel López-Brea
    • 1
  • Maria Jose Martinez
    • 2
  • Diego Domingo
    • 1
  • Isabel Sanchez Romero
    • 1
  • Juan Carlos Sanz
    • 1
  • Teresa Alarcón
    • 1
  1. 1.Department of MicrobiologyHospital Universitario de la PrincesaMadridSpain
  2. 2.Gastroenterology UnitHospital del Niño JesúsMadridSpain

Personalised recommendations